

References

California Prenatal Screening Program cfDNA Clinical Overview Webinar April 18, 2022

1. ACOG Practice Bulletin 226: Screening for Fetal Chromosomal Abnormalities. *Obstet Gynecol*, Vol 136, No 4, October 2020. <https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2020/10/screening-for-fetal-chromosomal-abnormalities>
2. Gregg AR, Skotko BG, Benkendorf JL, Monaghan KG, Bajaj K, Best RG, Klugman S, Watson MS, Noninvasive prenatal screening for fetal aneuploidy 2016 update: a position statement of the American College of Medical Genetics and Genomics. *Genetics in Medicine*, 2016; 18: 1056-1065
3. Benn P, Rebarber P, Non-invasive prenatal testing in the management of twin pregnancies. *Prenatal Diagnosis*, September 2021; 41:10: 1233-1240
4. Palomaki GE, Chiu RWK, Pertile MD, Sidermans EA, Yaron Y, Vermeesch JR, Vora NL, Best, RG, Wilkins-Haug, International Society for Prenatal Diagnosis Position Statement: cell free (cf) DNA screening for Down syndrome in multiple pregnancies. *Prenatal Diagnosis*, September 2021; 41:10: 1222-1232
5. Palomaki GE, Kloza EM. Prenatal cell-free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing, *Genetics in Medicine*; April 2018
6. Society for Maternal Fetal Medicine, Norton ME, Biggo JR, Kuller JA, Blackwell SC, The role of ultrasound in women who undergo cell-free DNA screening. Society for Maternal Fetal Medicine (SMFM) Consult Series #42 March 2017, [https://www.ajog.org/article/S0002-9378\(17\)30105-9/pdf](https://www.ajog.org/article/S0002-9378(17)30105-9/pdf)
7. Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, Tomlinson MW, Pereira L, Spitz JL, Holleman D, Cuckle H, Musci TJ, Wapner RJ. Cell-free DNA Analysis for Noninvasive Examination of Trisomy, *New England Journal of Medicine*; 2015;372: 1589-97
8. Wang J, Sahoo T, Schonberg S, Ross L, Patek K, Strom C, Discordant noninvasive prenatal testing and cytogenetic results: a study of 109 consecutive cases. 2015; 17:3:234-236
9. Dar P, Curnow KJ, Gross SJ, Hall MP, Stosic M, Demko Z, Zimmerman B, Hill M, Sigurjonsson, Ryan A, Banjevic M, Kolack PL, Koch SW, Strom CM, Rabinowitz M, Benn P, Clinical experience and follow-up with large scale single nucleotide polymorphism based noninvasive prenatal aneuploidy testing. *Am J Obstet Gynecol*, 201; 211(5):527.e1-527.e17
10. Dobson LJ, Reiff ES, Little SE, Wilkins-Haug L, Bromley B. Patient choice and clinical outcomes following positive noninvasive prenatal screening for aneuploidy with cell free DNA (cfDNA), *Prenatal Diagnosis*, 2016; 36(5): 456-62
11. Wapner R, Martin CL, Levy B et al. Chromosomal Microarray versus Karyotyping for Prenatal Diagnosis, *New England Journal of Medicine*, December 2012, 367: 2175-2184

12. Schwartz S, Kohan M, Pasion R, Papernhausen PR, Platt LD, Clinical experience of laboratory follow-up with non-invasive prenatal testing using cell-free DNA and positive microdeletion results in 349 cases, *Prenatal Diagnosis*, 2018; 38(2):210-218
13. Bianchi, D. Pregnancy: Prepare for unexpected prenatal test results. *Nature* **522**, 29–30 (2015). <https://doi.org/10.1038/522029a>
14. Grace MR, Hardisty E, Dotters-Katz SK, vora NL, Kuller JA. Cell-free DNA Screening: Complexities and Challenges of Clinical Implementation, *Obstet Gynecol Surv*; August 2016; 71(8):477-487
15. Norton ME, Baer RJ, Wapner RJ, Kuppermann M, Jeliffe-Pawlowski LL, Currier RJ. Cell free DNA vs sequential screening for the detection of fetal chromosomal abnormalities, *Am J Obstet Gynecol*; 2016; 214:727
16. Bianchi DW, Parker L, Wentworth J, Madankumar R, saffer C, Das A, Craig JA, Chudova DI, Devers PL, Jones KW, Oliver K, Rava RP, Sehnert AJ. DNA Sequencing versus Standard Prenatal Aneuploidy Screening, *New England Journal of Medicine*; 2014;370: 799-808
17. Bianchi DW, Cherchez la femme: meternal incidental findings can explain discordant prenatal cell-free DNA sequencing results. *Genetics in Medicine*; December 2017
18. Hui L, Bianchi DW, Fetal fraction and non-invasive prenatal testing: What clinicians need to know. *Prenatal Diagnosis*; 2020; 40:155-163
19. Gil MM, Galeva S, Jani J, Konstantinidou L, Akolekar R, Plana MN and Nicolaides KH, Screening for trisomies by cfDNA of maternal blood in twin pregnancy: update of the Fetal Medicine foundation results and meta-analysis. *Ultrasound Obstet Gynecol*. 2019; 53:734-742
20. Lo D, Corbetta N, Chamberlin PF, Rai V, sargent IL, Redman CWG et al. Presence of fetal DNA in maternal plasma and serum. *The Lancet*, 1997; 350:9076:485-487
21. Williams J, Rad S, Beauchamp S, Ratousi D, Subramaniam V, Farivar S, Pisarka MD, Utilization of noninvasive prenatal testing: impact of referrals for diagnostic testing. *Am J Obstet Gynecol*, 2015; 213: 102.e1-6
22. Snyder MW, Simmons LE, Kitzman JO et al. Copy-Number Variation and False Positive Prenatal Aneuploidy Screening Results, *New England Journal of Medicine*, 2015; 372: 1639-1645
23. Meschino WS, Miller K, Bedford MH, Incidental Detection of Familial APP Duplication: An Unusual Reason for a False Positive NIPT Result of Trisomy 21. *Obstetrical & Gynecological Survey*, 2016; 71(8):460-461
24. Bianchi DW, Chudova D, Sehnert AJ et al. Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies, *JAMA*, 2015;314(2): 162-169
25. Lenaerts L, Jatsenko T, Amant F, Vermeesch JR, Noninvasive Prenatal Testing and Detection of Occult Maternal Malignancies, *Clinical Chemistry*, 2019; 65(12):1484-1486
26. Amant F, Verheecke M, Wlodarska I, Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing, *JAMA Oncology*, 2015; 1(6):814-819
27. Taglauer ES, Wilkins-Haug L, Bianchi DW, Review: Cell-free fetal DNA in the maternal circulation as an indication of placental health and disease, *Placenta*, 2014; 35(Suppl): S64-S68

28. Hudecova I, Sahota D, Hueng MMS et al. Maternal Plasma Fetal DNA Fractions in Pregnancies with Low and High Risks for Fetal Chromosomal Aneuploides, *PLOS ONE*, 2014; 9(2): e88484
29. Dar P, Jacobsson B, MacPherson C et al. Cell-free DNA screening for trisomies 21, 18 and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation. *AJOG*, 2022; <https://doi.org/10.1016/j.ajog.2022.01.019>